Blueprint Medicines Corp (NASDAQ: BPMC) has reported E.P.S. of $-0.80 for its second fiscal quarter (ending June 30) versus $-2.19 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $-3.39 versus $-9.23 for the same period a year ago.
Recent Price Action
Blueprint Medicines Corp (NASDAQ: BPMC) stock suffered a large decline of -7.4% on 8/1/24. The stock closed at $100.29. Moreover, exceptionally high trading volume at 451% of normal accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -12.8% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, BPMC is expected to be a modest Value Builder.
Blueprint Medicines has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Blueprint Medicines has a very low Appreciation Score of 1 but a very high Power Rating of 87, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment